Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet...

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Invasive fungal infections (IFIs) present significant treatment challenges due to emerging pathogens, resistance, and a limited antifungal drug arsenal.
• Current antifungal drugs are constrained by toxicity, drug interactions, and a lack of oral formulations, complicating patient management.
• Antifungal drug development is further hindered by diagnostic limitations, clinical trial design issues, and patient recruitment difficulties.

Purpose of the Study:

• To summarize key discussions from a US Food and Drug Administration (FDA) workshop focused on invasive fungal infections (IFIs).
• To identify unmet needs and explore strategies for facilitating the development of new antifungal drugs for treatment and prophylaxis.
• To address challenges in antifungal drug development, including research support, nonclinical studies, and clinical trial design.

Main Methods:

• A workshop was convened by the US FDA on August 4, 2020.
• Experts from academia, industry, and government agencies participated in the workshop.
• The article summarizes topics presented and discussed during the workshop.

Main Results:

• Key topics included incentives and research support for antifungal drug developers.
• Challenges in nonclinical development and clinical trial design were discussed.
• Lessons learned from industry and potential collaborations were highlighted.

Conclusions:

• Facilitating antifungal drug development requires addressing limitations in diagnostics, clinical trials, and patient recruitment.
• Incentives, research support, and strategic collaborations are crucial for advancing new antifungal therapies.
• Overcoming the multifaceted challenges in IFI treatment necessitates a coordinated effort among stakeholders.